Sernova Biotherapeutics Inc. is a Canada-based clinical-stage company, which is focused on developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cell-derived cell therapies to create bio-hybrid organs to treat chronic diseases. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on type 1 diabetes (T1D) and thyroid disorders. Cell Pouch is a bio-hybrid organ which is surgically implanted beneath the skin of the abdomen.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Quotes

Date	Price	Change	Volume
27/10/26	CA$0.1100	0.00%	29,778
26/10/26	CA$0.1100	0.00%	70,630
23/10/26	CA$0.1100	0.00%	37,444
22/10/26	CA$0.1100	-8.33%	67,494
21/10/26	CA$0.1200	+9.09%	98,364

End-of-day quote Toronto S.E.

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.1100CAD

Average target price

1.000CAD

Spread / Average Target

+809.09%

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - Sernova Biotherapeutics Inc

Revisions to estimates

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Sernova Biotherapeutics Inc

Company calendar

End-of-day quote Toronto S.E. 27/10/2026			5-day change	1st Jan Change
0.1100 ^CAD	0.00%		0.00%	-15.38%

09-11	Sernova Biotherapeutics Inc Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2026	CI
09-08	Seraxis Holdings, Inc. entered into a definitive agreement to acquire Sernova Biotherapeutics Inc in a merger of equals, reverse merger transaction.	CI

Market Cap	41.54M 29.58M 26.54M 24.51M 22.23M 2.81B 42.05M 294M 117M 1.47B 111M 109M 4.67B	P/E 2026 *	-4.4x	P/E 2027 *	-3.67x
Enterprise Value	41.54M 29.58M 26.54M 24.51M 22.23M 2.81B 42.05M 294M 117M 1.47B 111M 109M 4.67B	EV / Sales 2026 *	-	EV / Sales 2027 *	16.6x
Free-Float	89.49%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Toronto S.E.	SVA	End-of-day quote
Toronto S.E.	SVA	Delayed
OTC Markets	SEOVF	Delayed
Tradegate	PSH0	Real-time
Deutsche Boerse AG	PSH0	Delayed
Börse Stuttgart	PSH0	Delayed
Xetra	PSH0	Delayed
Boerse Muenchen	PSH0	Real-time

09-11	Sernova Biotherapeutics Inc Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2026	CI
09-08	Seraxis Holdings, Inc. entered into a definitive agreement to acquire Sernova Biotherapeutics Inc in a merger of equals, reverse merger transaction.	CI
06-17	Sernova's Autologous Islet Transplantation Gets Orphan Drug Designation For Type 3c Diabetes Prevention	MT
06-12	Sernova Biotherapeutics Inc Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2026	CI
04-23	Sernova Biotherapeutics Inc announced that it has received CAD 7.564399 million in funding	CI
03-14	Sernova Biotherapeutics Inc Reports Earnings Results for the First Quarter Ended January 31, 2026	CI
03-04	Sernova Biotherapeutics Inc announced that it expects to receive CAD 7.1 million in funding	CI
12-20	Sernova Biotherapeutics Inc Reports Earnings Results for the Full Year Ended October 31, 2025	CI
12-19	Sernova Biotherapeutics Inc Auditor Raises 'Going Concern' Doubt	CI
11-13	Sernova Biotherapeutics Inc announced that it expects to receive CAD 5 million in funding	CI
23/09/25	Sernova Biotherapeutics Inc Appoints John L. Brooks III as Chair of the Board of Directors	CI
15/09/25	Sernova Biotherapeutics Inc Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2025	CI
09/07/25	Sernova Partners With Eledon Pharmaceuticals to Advance Potential Functional Cure for Type 1 Diabetes	MT

Sernova Biotherapeutics Inc Stock

Stocks

SVA

CA81752F1062

Medical Equipment, Supplies & Distribution

Valuation: Sernova Biotherapeutics Inc

Chart: Sernova Biotherapeutics Inc

Latest news: Sernova Biotherapeutics Inc

Press Releases: Sernova Biotherapeutics Inc

News in other languages: Sernova Biotherapeutics Inc

Quotes and Performance

Price Extremes

Managers and Directors: Sernova Biotherapeutics Inc

Latest insider transactions

Medical Devices & Implants

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

10-05	Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial	AQ
09-25	Sernova Biotherapeutics to Participate in Noble Capital Markets’ Emerging Growth Virtual Equity Conference	AQ
09-12	Steven Sangha Announces Voting and Support Agreement for Sernova Biotherapeutics Inc.'s Proposed Business Combination with Seraxis Holdings, Inc.	NE
09-10	Sernova Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investor Conference	AQ
09-08	Sernova and Seraxis Enter Definitive Merger Agreement to Create a Differentiated Type 1 Diabetes Islet Cell-Replacement Biotech Company, BetaNova Biotherapeutics	AQ

15/09/23	Sernova-Telefonkonferenz für Investoren, die ursprünglich für den 15. September geplant war, wird nun auf den 22. September verschoben
13/09/23	Sernova veranstaltet Telefonkonferenzen für Investoren zur Vorstellung der neu ernannten CEO und zur Bekanntgabe eines Updates zur Geschäftsentwicklung
03/05/23	AstraZeneca : accord de recherche avec le canadien Sernova
03/05/23	Sernova kündigt Forschungskooperation mit dem Pharmakonzern AstraZeneca an, um neuartige potenzielle Zelltherapie-Anwendungen zu untersuchen
10/04/23	Sernova präsentiert beim 2023 Cell & Gene Meeting on the Med der Alliance for Regenerative Medicine

Current month	+4.76%
1 month	+22.22%
3 months	-8.33%
6 months	-35.29%
Current year	-15.38%

1 week	0.1	0.12
1 month	0.09	0.12
Current year	0.08	0.2
1 year	0.08	0.2
3 years	0.08	0.82
5 years	0.08	2.22
10 years	0.08	2.87

Manager	Title	Age	Since
Jonathan Rigby CEO	Chief Executive Officer	59	12/08/2024
Marie Kaldchibachi DFI	Director of Finance/CFO	-	01/11/2023
James Parsons DFI	Director of Finance/CFO	61	07/10/2024

Director	Title	Age	Since
Steven Sangha BRD	Director/Board Member	-	24/04/2023
Jonathan Rigby CHM	Chairman	59	02/06/2025
David Paterson BRD	Director/Board Member	-	01/09/2024

Date	Insider	Type	Main position	Quantity	% Market Cap.
03/07/26	SERNOVA BIOTHERAPEUTICS, INC.	Sell	Company	-115,000	0.0305%
22/05/26	John Brooks	Option	Chairman	228,912	0.0658%
22/05/26	Steven Sangha	Option	Director	260,000	0.0748%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SERNOVA BIOTHERAPEUTICS INC	0.00%	0.00%	-31.25%	-85.14%	29.58M
ABBOTT LABORATORIES	-1.70%	+0.63%	-18.93%	+11.04%	178B
STRYKER CORPORATION	-1.54%	-0.98%	-21.45%	+15.09%	116B
MEDTRONIC PLC	-0.89%	-0.72%	-0.19%	+35.32%	115B
ESSILORLUXOTTICA	-2.42%	+2.07%	-44.13%	+5.42%	93.1B
CENCORA, INC.	-1.40%	-5.21%	-3.18%	+73.40%	62.09B
HOYA CORPORATION	+0.17%	-0.34%	+10.87%	+84.40%	55.87B
BECTON, DICKINSON AND COMPANY	-0.69%	+0.63%	+4.27%	-22.48%	53.12B
IDEXX LABORATORIES, INC.	-1.57%	+0.60%	-13.31%	+43.41%	44.22B
ALCON INC.	-1.09%	+1.72%	-4.34%	-9.94%	33.59B
Average	-0.83%	+1.21%	-12.16%	+15.05%	75.1B
Weighted average by Cap.	-0.86%	+2.37%	-13.43%	+23.89%

	2026 *	2027 *
Net sales	-	2.5M 1.78M 1.6M 1.48M 1.34M 169M 2.53M 17.68M 7.02M 88.62M 6.68M 6.54M 281M
Net income	-11.3M -8.05M -7.22M -6.67M -6.05M -764M -11.44M -79.94M -31.75M -401M -30.2M -29.55M -1.27B	-13.9M -9.9M -8.88M -8.2M -7.44M -940M -14.07M -98.33M -39.05M -493M -37.15M -36.35M -1.56B
Net Debt	-	-